Interestingly, an early increase in IL-10 is observed in patients with severe COVID-19; this could be explained both by the fact that IL-10 may not be able to properly modulate the immune response in severe SARS-CoV-2 infection, as seen in diabetic subjects who are known to have more severe disease [31] or IL-10 could deviate from its classical immunomodulatory action and act as an immunostimulant cytokine in some diseases as well as in severe COVID-19 [32]. Here, IL10 is linked to COVID-19.